Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jeffm34on Mar 20, 2021 1:26pm
146 Views
Post# 32845193

RE:RE:New poster on liver inflammation at Endo

RE:RE:New poster on liver inflammation at EndoAbstract disclosures. Does this mean some of these other companies sponsored this research paper as well ?   
Disclosures
  T.L. Stanley: Advisory Board Member; Self; Theratechnologies, Inc.. Grant Recipient; Self; Novo Nordisk. L.T. Fourman: Advisory Board Member; Self; Theratechnologies, Inc.. L. Wong: None. R. Sadreyev: None. J.T. Billingsley: Grant Recipient; Self; Boehringer IngelheimM.N. Feldpausch: None. A. Boutin: None. H. Lee: None. K.E. Corey: Consulting Fee; Self; Novo Nordisk, Gilead. Grant Recipient; Self; Bristol-Myers Squibb, Boehringer IngelheimM. Torriani: None. D. Kleiner: None. R.T. Chung: Grant Recipient; Self; Boehringer Ingelheim, Gilead, Merck, Roche Pharmaceuticals, Janssen Pharmaceuticals, Bristol-Myers Squibb. C.M. Hadigan: None. S.K. Grinspoon: Consulting Fee; Self; Theratechnologies, Inc.. Other; Self; Theratechnologies, Inc..
<< Previous
Bullboard Posts
Next >>